Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Diaminocyclohexane platinum

Perez-Soler, R., Khokhar, A. R., Hacker, M. P., and Lopez-Berestein, G. (1986). Toxicity and antitumor activity of cis-bis-cyclopentenecarboxylato-1,2-diaminocyclohexane platinum(II) encapsulated in multilamellar vesicles. Cancer Res., 46. 6269-6273. [Pg.331]

The second criteria, a different activity spectrum, is met by oxaliplatin (Figure 1.9A), the l isomer of [oxalatol f ra/rv-1,2-diaminocyclohexane)platinum (II)], oxaliplatin, [Pt(II)(oxalato)(DACH)]. This platinum agent is used for secondary treatment of metastatic colorectal cancer.77 Oxaliplatin, like carboplatin, has a kinetically slower leaving group, and is also less nephrotoxic than cisDDP. The limiting toxicity of oxaliplatin is peripheral sensory neuropathy, also seen with cisDDP. The neuropathy affects the extremities and increases in incidence and... [Pg.290]

Oxaliplatin is a third generation diaminocyclohexane platinum analog. Its mechanism of action is identical to that of cisplatin and carboplatin. However, it is not cross-resistant to cancer cells that are resistant to cisplatin or carboplatin on the basis of mismatch repair defects. This agent was recently approved for use as second-line therapy in metastatic colorectal cancer following treatment with the combination of fluorouracil-leucovorin and irinotecan, and it is now widely used as first-line therapy of this disease as well. Neurotoxicity is dose-limiting and characterized by a peripheral sensory neuropathy, often triggered or worsened upon exposure to cold. While this neurotoxicity is cumulative, it tends to be reversible—in contrast to cisplatin-induced neurotoxicity. [Pg.1289]

D. P. Kelsen, H. Scher, J. Burchenal, Phase I and Early Phase II Trials of 4 -Carboxyphthalato(l,2-Diaminocyclohexane)Platinum(II), in Platinum Coordination Complexes in Cancer Chemotherapy , Eds. M. P. Hacker, E. B. Douple, I. H. Krakoff, Martinus Nijhoff, Boston, 1984, p. 310. [Pg.61]

Cabral, H. Nishiyama, N. Okazaki, S. Koyama, H. Kataoka, K. Rreparation and biological properties of dichloro(l,2-diaminocyclohexane)platinum(ll) (DACHRt)-loaded polymeric micelles. J. Control. Release 2005, 101, 223-232. [Pg.209]

Recently complexes such as 13 and 14 have been prepared. They are based on the coupling of the DACH-Pt [(R,R)-trans-l,2-diaminocyclohexane-platinum(II)] fragment, the active part of oxaliplatin which is used in the treatment of colorectal cancer [64, 65], to tamoxifen (Scheme 3.6) [66]. [Pg.69]

Maleic copolymers were proved to form chelates with platinum-containing anticancer drugs (cis-diamminedichloroplatinum(II), trans-l,2-diaminocyclohexane platinum) through a monocarboxylato and a 0->Pt coordination linkage. These complexes self-assembled into nanoparticles with an increased in-vivo tumors inhibition due to their internalization into the cancer cells. The release of the platinum-containing drug was pH dependent [211,212]. [Pg.295]

These acid groups are subsequently reacted with a platinum-containing moiety such as /rani-1,2-diaminocyclohexane platinum(ll) salt, forming the following platinum-containing polymer ... [Pg.178]


See other pages where Diaminocyclohexane platinum is mentioned: [Pg.326]    [Pg.290]    [Pg.201]    [Pg.1170]    [Pg.80]    [Pg.155]    [Pg.123]    [Pg.2408]    [Pg.129]    [Pg.135]    [Pg.282]    [Pg.283]    [Pg.290]    [Pg.173]    [Pg.272]    [Pg.254]    [Pg.258]    [Pg.282]    [Pg.283]    [Pg.290]    [Pg.161]    [Pg.179]   
See also in sourсe #XX -- [ Pg.135 ]




SEARCH



1,2-diaminocyclohexane

Diaminocyclohexanes

© 2024 chempedia.info